|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mechanistically, MH renal-protection from DN may be related to lipid metabolic improvement and oxidative stress attenuation along with increases in AMPK/PGC-1α/CPT1B-mediated fatty acid oxidation and Nrf2/SOD2-mediated anti-oxidative stress.
|
30876865 |
2019 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Hesperidin alleviates BLM-induced IPF via inhibition of TGF-β1/Smad3/AMPK and IκBα/NF-κB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-α, IL-1β, and IL-6) to reduce collagen deposition during pulmonary fibrosis.See also Figure 1(Fig.1).
|
31611754 |
2019 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bleomycin (BLM)-induced PF in Nrf2-knockout (Nrf2<sup>-/-</sup> ) and wild-type (WT) mice and transforming growth factor β1 (TGF-β1)-induced EMT in rat type II alveolar epithelial cell line (RLE-6TN) and human alveolar epithelial cell line (A549) were established to observe the relationship among Nrf2, HMGB1, and EMT by western blot and immunohistochemistry.
|
30370641 |
2019 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tanshinone IIA Activates Nuclear Factor-Erythroid 2-Related Factor 2 to Restrain Pulmonary Fibrosis via Regulation of Redox Homeostasis and Glutaminolysis.
|
30105924 |
2019 |
|
Pulmonary Fibrosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Amitriptyline attenuates bleomycin-induced pulmonary fibrosis: modulation of the expression of NF-κβ, iNOS, and Nrf2.
|
30474696 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we discovered that overexpression of antioxidant-responsive element (ARE)-containing Nrf2 target genes by increased transactivation of Nrf2 occurred because of an acquired Keap1 mutation in the gefitinib-resistant (GR) NSCLC cell line we established.
|
29812969 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specifically, Nrf2 plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and we found that combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro.
|
29857117 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both Nrf2 overexpression and Beclin1 lower-expression are independent indicators of a poor prognosis in NSCLC patients.
|
30160218 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Targeting Nrf2-mediated heme oxygenase-1 enhances non-thermal plasma-induced cell death in non-small-cell lung cancer A549 cells.
|
30248308 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study a traditional Chinese medicine, triptolide, was identified that markedly inhibited expression and transcriptional activity of Nrf2 in various cancer cells, including NSCLC and liver cancer cells.
|
30196066 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our previous study indicated that Casein kinase 2 interacting protein-1 (CKIP-1) could promote the activation of the nuclear factor E2-related factor 2 (Nrf2)/ antioxidant response element (ARE) pathway, playing a significant role in inhibiting the fibrosis of diabetic nephropathy (DN).
|
29248720 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
We hypothesized that MDM2 enhances NRF2 antioxidant signaling in DKD given that MDM2 is a key negative regulator of P53.
|
29704532 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that PHLPP1 up-surged Nrf2 nuclear instability by promoting Nrf2/β-TrCP association and its inhibition may be critical in the management of diabetic nephropathy.
|
29655866 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Luciferase reporter assay and western blot further revealed that miR-27a directly targeted the 3' untranslated region (UTR) of nuclear factor erythroid 2-like 2 (Nrf2) and reduced its expression in type 2 DN.
|
30103116 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Given the critical role of NRF2 in preventing DN, the present study aimed to test whether or not NRF2 is required for SP600125's protection against DN.
|
29273684 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
M1/M2 Macrophages in Diabetic Nephropathy: Nrf2/HO-1 as Therapeutic Targets.
|
30014796 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study was aimed at exploring whether AST exerts a protective effect on DN via activating nuclear factor erythroid 2-related factor 2- (Nrf2-) antioxidative response element (ARE) signaling.
|
29744366 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, these results suggest that CGA is a potential therapeutic agent in the treatment of DN due to its antioxidant and anti-inflammatory effects which are mediated via the modulation of the Nrf2/HO-1 and NF-ĸB pathways.
|
29161661 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibitors of CCL2/CCR2, IL-1β and JAK/STAT pathways, and Nrf2 inducers are promising therapeutic options to improve the renal outcome of patients with DN, but appropriate clinical trials are necessary.
|
30334635 |
2018 |
|
Diabetic Nephropathy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our data suggest that the renoprotective effect of AST on DN depends on Nrf2/ARE signaling activation, which could be a potentially therapeutic strategy in the treatment of DN.
|
29621130 |
2018 |
|
Pulmonary Fibrosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Salvianolic acid B inhibits myofibroblast transdifferentiation in experimental pulmonary fibrosis via the up-regulation of Nrf2.
|
29108993 |
2018 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that FGF21 inhibits pulmonary fibrosis through activating Nrf-2 pathway, subsequently suppressing oxidative stress, inhibiting ECM deposition and pulmonary fibrogenesis, suggesting that FGF21 has potential as therapeutic agent for treatment of pulmonary fibrosis.
|
29864937 |
2018 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we observed the effects of Nrf2 pathway and Numb on bleomycin(BLM)-induced PF in Nrf2-knockout (Nrf2<sup>-/-</sup>) and wild-type (WT) mice.
|
29362432 |
2018 |
|
Pulmonary Fibrosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We explore the possible discourse of sinapic acid (SA) against the prevention of bleomycin (BLM)-instigated lung fibrosis in rats through modulation of Nrf2/HO-1 and NF-κB signaling pathways.
|
30219680 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further identified an NRF2-regulated metabolic gene signature (NRMGS) by correlating the microarray data with lung adenocarcinoma RNA-Seq gene expression data from The Cancer Genome Atlas followed by qRT-PCR validation, and finally showed that higher expression of the signature conferred a poor prognosis in 8 independent NSCLC cohorts.
|
29050246 |
2017 |